Evidence for steroidogenic potential in human prostate cell lines and tissues

American Journal of Pathology

Volumn 181, Issue 3, 2012, Pages 1078-1087

  Bennett, Nigel C ^a   Hooper, John D ^b   Lambie, Duncan ^c   Lee, Cheok S ^d,e   Yang, Tao ^d,e   Vesey, David A ^a,c   Samaratunga, Hemamali ^f   Johnson, David W ^c   Gobe, Glenda C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Aquesta Pathology ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA3 HYDROXYSTEROID DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROSTANOLONE; CHOLESTEROL; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME; CYTOCHROME P450 17A1; MESSENGER RNA; OXIDOREDUCTASE; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; STEROIDOGENESIS; TESTOSTERONE SYNTHESIS;

ANDROGENS; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; MALE; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; RNA, MESSENGER; STEROIDS;

EID: 84865242183     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.06.009     Document Type: Article

References (30)

1. X. Yuan, T. Li, H. Wang, T. Zhang, M. Barua, R.A. Borgesi, G.J. Bubley, M.L. Lu, S.P. Balk Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells Am J Pathol 169 2006 682 696
2. B.J. Feldman, D. Feldman The development of androgen-independent prostate cancer Nat Rev Cancer 1 2001 34 45
3. G. Attard, D. Sarker, A. Reid, R. Molife, C. Parker, J.S. de Bono Improving the outcome of patients with castration-resistant prostate cancer through rational drug development Br J Cancer 95 2006 767 774
4. J.L. Mohler, C.W. Gregory, O.H. Ford III, D. Kim, C.M. Weaver, P. Petrusz, E.M. Wilson, F.S. French The androgen axis in recurrent prostate cancer Clin Cancer Res 10 2004 440 448
5. M.A. Titus, M.J. Schell, F.B. Lih, K.B. Tomer, J.L. Mohler Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin Cancer Res 11 2005 4653 4657
6. J.A. Locke, E.S. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, C.A. Wood, S.L. Ettinger, M.E. Gleave, C.C. Nelson Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 2008 6407 6415
7. N.C. Bennett, R.A. Gardiner, J.D. Hooper, D.W. Johnson, G.C. Gobe Molecular cell biology of androgen receptor signalling Int J Biochem Cell Biol 42 2010 813 827
8. D.M. Stocco, X. Wang, Y. Jo, P.R. Manna Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: more complicated than we thought Mol Endocrinol 19 2005 2647 2659
9. I.C. Guo, M.C. Hu, B.C. Chung Transcriptional regulation of CYP11A1 J Biomed Sci 10 2003 593 598
10. B.C. Chung, J. Picado-Leonard, M. Haniu, M. Bienkowski, P.F. Hall, J.E. Shively, W.L. Miller Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues Proc Natl Acad Sci U S A 84 1987 407 411
11. J.K. Wickenheisser, P.G. Quinn, V.L. Nelson, R.S. Legro, J.F. Strauss III, J.M. McAllister Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells J Clin Endocrinol Metab 85 2000 2304 2311
12. A. Slominski, G. Ermak, M. Mihm ACTH receptor CYP11A1, CYP17 and CYP21A2 genes are expressed in skin J Clin Endocrinol Metab 81 1996 2746 2749
13. J. Trachtenberg, J. Zadra Steroid synthesis inhibition by ketoconazole: sites of action Clin Invest Med 11 1988 1 5
14. J.A. Locke, L. Fazli, H. Adomat, J. Smyl, K. Weins, A.A. Lubik, D.B. Hales, C.C. Nelson, M.E. Gleave, E.S. Tomlinson Guns A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer Prostate 69 2009 928 937
15. J. Simard, M.L. Ricketts, S. Gingras, P. Soucy, F.A. Feltus, M.H. Melner Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family Endocr Rev 26 2005 525 582
16. F. Labrie, V. Luu-The, S.X. Lin, C. Labrie, J. Simard, R. Breton, A. Belanger The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology Steroids 62 1997 148 158
17. M. El-Alfy, V. Luu-The, X.F. Huang, L. Berger, F. Labrie, G. Pelletier Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry Endocrinology 140 1999 1481 1491
18. M. Stanbrough, G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, P.G. Febbo, S.P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
19. M.J. Pfeiffer, F.P. Smit, J.P. Sedelaar, J.A. Schalken Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer Mol Med 17 2011 657 664
20. L.A. Castagnetta, G. Carruba, A. Traina, O.M. Granata, M. Markus, M. Pavone-Macaluso, C.H. Blomquist, J. Adamski Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells Endocrinology 138 1997 4876 4882
21. J. Hofland, W.M. van Weerden, N.F. Dits, J. Steenbergen, G.J. van Leenders, G. Jenster, F.H. Schroder, F.H. de Jong Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer Cancer Res 70 2010 1256 1264
22. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
23. M.W. Pfaffl A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 29 2001 e45
24. J.H. Abalain, E. Quemener, J.L. Carre, B. Simon, Y. Amet, P. Mangin, H.H. Floch Metabolism of androgens in human hyperplastic prostate: evidence for a differential localization of the enzymes involved in the metabolism J Steroid Biochem 34 1989 467 471
25. A.H. Reid, G. Attard, E. Barrie, J.S. de Bono CYP17 inhibition as a hormonal strategy for prostate cancer Nat Clin Pract Urol 5 2008 610 620
26. L. True, I. Coleman, S. Hawley, C.Y. Huang, D. Gifford, R. Coleman, T.M. Beer, E. Gelmann, M. Datta, E. Mostaghel, B. Knudsen, P. Lange, R. Vessella, D. Lin, L. Hood, P.S. Nelson A molecular correlate to the Gleason grading system for prostate adenocarcinoma Proc Natl Acad Sci U S A 103 2006 10991 10996
27. G. Attard, A.H. Reid, T.A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, J. Clark, C.S. Cooper, S.B. Kaye, D. Dearnaley, G. Lee, J.S. de Bono Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
28. A. O'Donnell, I. Judson, M. Dowsett, F. Raynaud, D. Dearnaley, M. Mason, S. Harland, A. Robbins, G. Halbert, B. Nutley, M. Jarman Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer Br J Cancer 90 2004 2317 2325
29. A.A. Lubik, J.H. Gunter, S.C. Hendy, J.A. Locke, H.H. Adomat, V. Thompson, A. Herington, M.E. Gleave, M. Pollak, C.C. Nelson Insulin increases de novo steroidogenesis in prostate cancer cells Cancer Res 71 2011 5754 5764
30. N. Fu, I. Drinnenberg, J. Kelso, J.R. Wu, S. Paabo, R. Zeng, P. Khaitovich Comparison of protein and mRNA expression evolution in humans and chimpanzees PloS One 2 2007 e216